PitchBook-2025年二季度医疗科技VC和PE趋势（英）-2025.8_9页_6mb

Medtech Sector Overview (Q2 2025)

• VC Activity: Medtech received $4.1B in Q2 2025, just below Q1's $4.4B, but still marking one of the most valuable quarters for the sector. Surgical devices & tools were the most active segment in Q2, comprising 46% of deal value and 30% of total transactions. Surgeons are strategic targets, as shown by the $650M Series E for Neuralink and $250M raise for Kardium. Diagnostics saw Function Health achieve unicorn status with a $300M Series B.
• Deal Distribution: Despite a decline in overall deal count by 10.4% compared to the previous year, the composition of investments shifted significantly. Surgical tools surpassed diagnostics in funding received ($13.6B vs. $7.6B), suggesting a strategic realignment that began in 2023.
• Investment Trends: Activity showcases a clear market concentration toward AI-native startups and well-established platforms, especially at larger valuations. This follows broader VC trends towards larger rounds and maturation-focused later-stage investment.

Key Highlights by Segment

• Surgical Devices & Tools: Dominated Q2 activity: 46% of deal value, 30% of count. Key players include Neuralink ($650M Series E), Kardium ($250M), and OrganOx ($160M).
• Diagnostics & Life Sciences: Second most active, comprising roughly 28% of the total deal count and contributing 19% of deal value.
• Remote Monitoring & Portable Care, Medical Imaging, Nonsurgical Treatments: These segments saw specific notable investments but held a smaller share of the overall activity this quarter.
• VC Deal Value Growth: While deal numbers decreased, the average deal value increased significantly, signaling a concentration of investment into fewer, more mature firms.

PE and Exit Activity

• PE: Recorded its highest annual total to date, with nearly $5B invested in ~60 deals through the first two quarters, up sharply from 2020 ($9.2B in 2024).
• Exits: CC and exits slowed dramatically this year compared to 2024, with only 14 exits recorded through Q2. The largest exit value to date resulted from an IPO.

Stage Dynamics and Future Outlook

• VC Stage Focus: Overall VC activity in medtech declined in Q2, yet funding specifically for later stages (Series E+ and beyond, plus venture-growth) increased notably (+~25%) while slightly more later-stage companies received investment relative to earlier stages.
• Longer Horizons: Firms are increasingly seeking later-stage capital, reflecting reduced exit velocity and extended investment cycles in medtech (with fewer public listings and M&A activity).

Summary Conclusion

Q2 2025 marked a strong continued performance for medtech, though the pace of deal flow declined compared to prior quarters/years. A consolidation toward the surgical devices segment and AI capabilities is apparent. VC activity remains robust in funding but exits lagged. With deals significantly larger in value and investments moving through later stages, medtech is navigating a period of high contribution to VC/PE funds, underpinned by strong R&D but potentially extended growth cycles.